Precision medicine in Thoracic Oncology: understanding disparities to tackle inequities in access

References

• Deininger MW. Milestones and monitoring in patients with CML treated with Imatinib. Hematology. 2008;2008(1):419–426. doi: 10.1182/asheducation-2008.1.419
   Google Scholar
• Howlader N, Forjaz G, Mooradian MJ, et al. The effect of Advances in lung-cancer treatment on population mortality. N Engl J Med [Internet]. 2020;383(7):640–649. [cited 2021 Feb 21]. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1916623
   PubMed Web of Science ®Google Scholar
• Mok T, Camidge DR, Gadgeel SM, et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol. 2020;31(8):1056–1064. doi: 10.1016/j.annonc.2020.04.478
   PubMed Web of Science ®Google Scholar
• Slatko BE, Gardner AF, Ausubel FM. Overview of Next‐generation sequencing technologies. Curr Protoc Mol Biol. 2018;122(1):122. doi: 10.1002/cpmb.59
   Google Scholar
• Magi A, Benelli M, Gozzini A, et al. Bioinformatics for next generation sequencing data. Genes (Basel). 2010;1(2):294–307. doi: 10.3390/genes1020294
   PubMed Web of Science ®Google Scholar
• Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med [Internet]. 2015;372(26):2509–2520. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26028255
   PubMed Web of Science ®Google Scholar
• Salama AKS, Li S, Macrae ER, et al. Dabrafenib and trametinib in patients with tumors with BRAF V600E mutations: results of the NCI-MATCH trial subprotocol H. J Clin Oncol. 2020;38(33):3895–3904. doi: 10.1200/JCO.20.00762
   PubMed Web of Science ®Google Scholar
• Drilon A, Laetsch TW, Kummar S, et al. Efficacy of Larotrectinib in TRK fusion–positive cancers in adults and children. N Engl J Med. 2018;378(8):731–739. doi: 10.1056/NEJMoa1714448
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin [Internet]. 2021;71(3):209–249. Available from: https://onlinelibrary.wiley.com/doi/10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Wood DE, Chair V, Aisner DL, et al. NCCN guidelines version 3.2019 non-small cell lung cancer [Internet]. 2019 [cited 2019 Jan 30]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
   Google Scholar
• Robert NJ, Nwokeji ED, Espirito JL, et al. Biomarker tissue journey among patients (pts) with untreated metastatic non-small cell lung cancer (mNSCLC) in the U.S. Oncology network community practices. J Clin Oncol. 2021;39(15_suppl):9004–9004. doi: 10.1200/JCO.2021.39.15_suppl.9004
   Web of Science ®Google Scholar
• Adizie JB, Tweedie J, Khakwani A, et al. Biomarker testing for people with advanced lung cancer in England. JTO Clin Res Rep. 2021;2(6):100176. doi: 10.1016/j.jtocrr.2021.100176
   PubMedGoogle Scholar
• Provencio M, Cobo M, Rodriguez-Abreu D, et al. Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics. BMC Cancer. 2022;22(1):732. doi: 10.1186/s12885-022-09830-8
   PubMed Web of Science ®Google Scholar
• Matsumoto S, Ikeda T, Yoh K, et al. Impact of rapid multigene assays with short turnaround time (TAT) on the development of precision medicine for non-small cell lung cancer (NSCLC). J Clin Oncol. 2021;39(15_suppl):9094–9094. doi: 10.1200/JCO.2021.39.15_suppl.9094
   Web of Science ®Google Scholar
• Bruno DS, Hess LM, Li X, et al. Racial disparities in biomarker testing and clinical trial enrollment in non-small cell lung cancer (NSCLC). J Clin Oncol. 2021;39(15_suppl):9005–9005. doi: 10.1200/JCO.2021.39.15_suppl.9005
   Web of Science ®Google Scholar
• Lynch JA, Berse B, Rabb M, et al. Underutilization and disparities in access to EGFR testing among medicare patients with lung cancer from 2010 – 2013. BMC Cancer. 2018;18(1):306. doi: 10.1186/s12885-018-4190-3
   PubMedGoogle Scholar
• Kehl KL, Lathan CS, Johnson BE, et al. Race, poverty, and initial implementation of precision medicine for lung cancer. JNCI. 2019;111(4):431–434. doi: 10.1093/jnci/djy202
   PubMedGoogle Scholar
• Kembou Nzale S, Weeks WB, Ouafik L, et al. Inequity in access to personalized medicine in France: evidences from analysis of geo variations in the access to molecular profiling among advanced non-small-cell lung cancer patients: results from the IFCT biomarkers France study. PLoS One. 2020;15(7):e0234387. doi: 10.1371/journal.pone.0234387
   PubMed Web of Science ®Google Scholar
• Smeltzer MP, Wynes MW, Lantuejoul S, et al. The International association for the study of lung cancer global survey on molecular testing in lung cancer. J Thorac Oncol. 2020;15(9):1434–1448. doi: 10.1016/j.jtho.2020.05.002
   PubMed Web of Science ®Google Scholar
• Duarte FA, Ferreira CG, Dienstmann R, et al. Barriers in precision medicine implementation among advanced nonsquamous cell lung cancer-patients: a real-world evidence scenario. J Mark Access Health Policy. 2022;10(1):10. doi: 10.1080/20016689.2022.2077905
   Google Scholar
• Al-Kateb H, Nguyen TT, Steger-May K, et al. Identification of major factors associated with failed clinical molecular oncology testing performed by next generation sequencing (NGS). Mol Oncol. 2015;9(9):1737–1743. doi: 10.1016/j.molonc.2015.05.004
   PubMed Web of Science ®Google Scholar
• Claudio M, Mauricio C, Olga B, et al. Real‑world evaluation of molecular testing and treatment patterns for EGFR mutations in non‑small cell lung cancer in Latin America. Mol Clin Oncol. 2021;16(1):6. doi: 10.3892/mco.2021.2439
   PubMed Web of Science ®Google Scholar
• Bach PB, Cramer LD, Warren JL, et al. Racial differences in the treatment of early-stage lung cancer. N Engl J Med. 1999;341(16):1198–1205. doi: 10.1056/NEJM199910143411606
   PubMed Web of Science ®Google Scholar
• Forrest LF, Adams J, Wareham H, et al. Socioeconomic inequalities in lung cancer treatment: systematic review and meta-analysis. PLoS Med. 2013;10(2):e1001376. doi: 10.1371/journal.pmed.1001376
   PubMed Web of Science ®Google Scholar
• Compton CC, Robb JA, Anderson MW, et al. Preanalytics and precision pathology: pathology practices to ensure molecular integrity of cancer patient biospecimens for precision medicine. Arch Pathol Lab Med. 2019;143(11):1346–1363. doi: 10.5858/arpa.2019-0009-SA
   PubMed Web of Science ®Google Scholar
• Feero WG, Green ED. Genomics education for Health care professionals in the 21st Century. JAMA. 2011;306(9). doi: 10.1001/jama.2011.1245
   PubMed Web of Science ®Google Scholar
• Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. Genet Med. 2015;17(5):405–424. doi: 10.1038/gim.2015.30
   PubMed Web of Science ®Google Scholar
• Bourret P, Cambrosio A. Genomic expertise in action: molecular tumour boards and decision‐making in precision oncology. Sociol Health Illn. 2019;41(8):1568–1584. doi: 10.1111/1467-9566.12970
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Adams R, Tabernero J, et al. Awareness, understanding, and adoption of precision medicine to deliver personalized treatment for patients with cancer: a multinational survey comparison of physicians and patients. Oncology. 2016;21(3):292–300. doi: 10.1634/theoncologist.2015-0279
   Google Scholar
• Chen Y, Guzauskas G, Gu C, et al. Precision Health economics and outcomes research to support precision medicine: big data meets patient heterogeneity on the road to value. J Pers Med. 2016;6(4):20. doi: 10.3390/jpm6040020
   PubMedGoogle Scholar
• Faulkner E, Annemans L, Garrison L, et al. Challenges in the development and reimbursement of personalized medicine—payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR personalized medicine special interest group. Value Health [Internet]. 2012;15(8):1162–1171. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1098301512016129
   PubMed Web of Science ®Google Scholar
• GoodSmith MS, Skandari MR, Huang ES, et al. The impact of biomarker screening and cascade genetic testing on the cost-effectiveness of MODY genetic testing. Diabetes Care. 2019;42(12):2247–2255. doi: 10.2337/dc19-0486
   PubMed Web of Science ®Google Scholar
• Pisapia P, Pepe F, Baggi A, et al. Next generation diagnostic algorithm in non-small cell lung cancer predictive molecular pathology: the KWAY Italian multicenter cost evaluation study. Crit Rev Oncol Hematol. 2022;169:103525. doi: 10.1016/j.critrevonc.2021.103525
   PubMed Web of Science ®Google Scholar
• Weymann D, Pataky R, Regier DA. Economic evaluations of Next-generation precision oncology: a critical review. JCO Precis Oncol. 2018;2:1–23. doi: 10.1200/PO.17.00311
   PubMedGoogle Scholar
• Lieberthal RD, Dudash K, Axelrod R, et al. An economic model to value companion diagnostics in non-small-cell lung cancer. Per Med. 2013;10(2):139–147. doi: 10.2217/pme.13.7
   PubMed Web of Science ®Google Scholar
• Doble B, John T, Thomas D, et al. Cost-effectiveness of precision medicine in the fourth-line treatment of metastatic lung adenocarcinoma: an early decision analytic model of multiplex targeted sequencing. Lung Cancer. 2017;107:22–35. doi: 10.1016/j.lungcan.2016.05.024
   PubMed Web of Science ®Google Scholar
• Schluckebier L, Caetano R, Garay OU, et al. Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients. BMC Cancer. 2020;20(1):875. doi: 10.1186/s12885-020-07240-2
   PubMed Web of Science ®Google Scholar